Published in Clin Cancer Res on January 12, 2010
A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One (2011) 1.05
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Knowledge boosting: a graph-based integration approach with multi-omics data and genomic knowledge for cancer clinical outcome prediction. J Am Med Inform Assoc (2014) 0.87
A network pharmacology approach to evaluating the efficacy of chinese medicine using genome-wide transcriptional expression data. Evid Based Complement Alternat Med (2013) 0.87
Intra-relation reconstruction from inter-relation: miRNA to gene expression. BMC Syst Biol (2013) 0.86
Shifting from population-wide to personalized cancer prognosis with microarrays. PLoS One (2012) 0.86
Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic? Cancers (Basel) (2011) 0.83
Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. BMC Bioinformatics (2011) 0.81
Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. Methods (2014) 0.81
Do DNA microarrays tell the story of gene expression? Gene Regul Syst Bio (2010) 0.80
Gene expression profiling in human lung development: an abundant resource for lung adenocarcinoma prognosis. PLoS One (2014) 0.80
Does applicability domain exist in microarray-based genomic research? PLoS One (2010) 0.80
A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. PLoS One (2013) 0.80
Determination of minimum training sample size for microarray-based cancer outcome prediction-an empirical assessment. PLoS One (2013) 0.79
Cross-platform comparison of microarray-based multiple-class prediction. PLoS One (2011) 0.79
Reverse engineering biomolecular systems using -omic data: challenges, progress and opportunities. Brief Bioinform (2012) 0.77
Gene Expression Profiling via Multigene Concatemers. PLoS One (2011) 0.76
Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res (2011) 0.75
Clinical usefulness of microarrays for cancer prognosis in 2010--letter. Clin Cancer Res (2010) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol (2006) 8.87
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
ISA software suite: supporting standards-compliant experimental annotation and enabling curation at the community level. Bioinformatics (2010) 5.60
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Toward interoperable bioscience data. Nat Genet (2012) 4.72
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
A strategy capitalizing on synergies: the Reporting Structure for Biological Investigation (RSBI) working group. OMICS (2006) 3.51
ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect (2003) 3.39
Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat Biotechnol (2006) 3.13
QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn (2004) 2.73
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Development of public toxicogenomics software for microarray data management and analysis. Mutat Res (2004) 2.29
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology (2013) 2.02
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. BMC Bioinformatics (2008) 1.98
Edematous erythema, subcutaneous plaques, and severe pain in the lower extremities in an immunocompromised patient. JAMA (2013) 1.97
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A (2012) 1.89
CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron (2009) 1.79
Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol (2013) 1.75
GOFFA: gene ontology for functional analysis--a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics (2006) 1.72
Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol (2007) 1.71
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol (2009) 1.67
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents (2009) 1.54
Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics (2011) 1.53
Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52. Altern Lab Anim (2005) 1.52
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2012) 1.49
Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PLoS One (2011) 1.49
A novel mutation within the 2B rod domain of keratin 9 in a Chinese pedigree with epidermolytic palmoplantar keratoderma combined with knuckle pads and camptodactyly. Eur J Dermatol (2011) 1.44
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int (2013) 1.41
Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. Chem Res Toxicol (2011) 1.41
Next-generation sequencing in the clinic: promises and challenges. Cancer Lett (2012) 1.39
Technical reproducibility of genotyping SNP arrays used in genome-wide association studies. PLoS One (2012) 1.36
Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum (2012) 1.34
Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn (2011) 1.33
Decision forest: combining the predictions of multiple independent decision tree models. J Chem Inf Comput Sci (2003) 1.32
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect (2002) 1.31
Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos (2010) 1.27
Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J Nutr (2002) 1.27
mRNA enrichment protocols determine the quantification characteristics of external RNA spike-in controls in RNA-Seq studies. Sci China Life Sci (2013) 1.26
A novel role of Brg1 in the regulation of SRF/MRTFA-dependent smooth muscle-specific gene expression. J Biol Chem (2007) 1.26
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. PLoS Comput Biol (2011) 1.26
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics (2005) 1.25
DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res (2011) 1.23